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The hypothesis that the Akt inhibitor, perifosine (PER), combined with inhibitors of glutathione (GSH) and thioredoxin (Trx)
metabolism will induce cytotoxicity via metabolic oxidative stress in human head and neck cancer (HNSCC) cells was tested.
PER induced increases in glutathione disulﬁde (%GSSG) in FaDu, Cal-27, and SCC-25 HNSCCs as well as causing signiﬁcant
clonogenic cell killing in FaDu and Cal-27, which was suppressed by simultaneous treatment with N-acetylcysteine (NAC). An
inhibitor of GSH synthesis, buthionine sulfoximine (BSO), sensitized Cal-27 and SCC-25 cells to PER-induced clonogenic killing
as well as decreased total GSH and increased %GSSG. Additionally, inhibition of thioredoxin reductase activity (TrxRed) with
auranoﬁn (AUR) was able to induce PER sensitization in SCC-25 cells that were initially refractory to PER. These results support
the conclusion that PER induces oxidative stress and clonogenic killing in HNSCC cells that is enhanced with inhibitors of GSH
and Trx metabolism.
Copyright © 2009 Andrean L. Simons et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Growing evidence exists that cancer cells are under increased
intrinsic metabolic oxidative stress compared to normal
untransformed cells due in part to mitochondrial dysfunc-
tion [1–3]. Studies have shown that defects in mitochondrial
respiration led to activation of the Akt (protein kinase B)
pathway, which may be an important mechanism by which
cancer cells use to survive under conditions of chronic
oxidative stress [4]. Akt is a serine-threonine protein kinase,
which has been shown to have a role in angiogenesis, cell
cycle progression, diﬀerentiation, and cell growth [5, 6].
Akt is hyperactivated in many cancer types including breast,
colorectal, ovarian, and especially head and neck cancer
(HNSCC) compared to normal tissue [7, 8], which led
to the hypothesis that metabolic oxidative stress may be
causally related to the increased Akt activity observed in
cancer cells. Given that the Akt pathway is critical for cell
survival,andcancercellshavebeensuggestedtodemonstrate
increased intracellular hydroperoxide production compared
to normal (untransformed) cells [2, 9–11], we propose that
tumor cells may increase Akt activity to compensate for
increased intracellular hydroperoxides and oxidative stress
causedbydefectsinmitochondrialrespiration.Furthermore,
weproposethattherapeuticinterventionsdesignedtoinhibit
Akt activation and hydroperoxide detoxiﬁcation combined
with manipulations that increase prooxidant production
would preferentially kill tumor cells versus normal cells via
oxidative stress.
Perifosine (Octadecyl-(1,1-dimethyl-piperidinio-4-yl)-
phosphate (PER)) is a bioavailable alkylphospholipid which
is currently being tested in phases 1 and 2 clinical trials
[12–17]a n di sam e m b e ro fal a r g e rg r o u po fm e m b r a n e
permeable single-chain antitumor alkylphosphocholines
(APCs) [18–20]. PER has shown signiﬁcant antiproliferative
activity in in vitro and in vivo tumor models including
breast, colon, prostate and HNSCC [18, 21]. Akt is a speciﬁc
target of PER by targeting the plekstrin homology (PH)
domain of Akt and preventing its translocation to the
plasma membrane to be activated [21]. The aim of the2 Journal of Oncology
present study is to determine if PER induces oxidative stress
and if disrupting thiol antioxidant metabolism pathways
further enhances sensitivity to PER-induced clonogenic cell
killing in HNSCC cells.
2.MaterialsandMethods
2.1. Cells and Culture Conditions. FaDu, Cal-27, and SCC-
25 human head and neck squamous carcinoma cells were
obtained from the American Type Culture Collection (Man-
assas, VA). FaDu and Cal-27 cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
4mM L-glutamine, 1mM sodium pyruvate, 1.5g/L sodium
bicarbonate,and4.5g/Lglucosewith10%fetalbovineserum
(FBS; Hyclone, Logan, UT). SCC-25 cells were maintained in
a 1 : 1 mixture of Dulbecco’s modiﬁed Eagle’s medium and
Ham’s F12 medium containing 1.2g/L sodium bicarbonate,
2.5mM L-glutamine, 15mM HEPES, 0.5mM sodium pyru-
vate, 4.5g/L glucose, and 400ng/mL hydrocortisone with
10% fetal bovine serum. Cultures were maintained in 5%
CO2 and humidiﬁed in a 37
◦C incubator.
2.2. Drug Treatment. N-acetyl cysteine (NAC) and L-
buthionine-[S,R]-sulfoximine (BSO) were obtained from
Sigma Chemical Co. (St. Louis, MO). Auranoﬁn (AUR) was
obtained from ICN Biochemicals (Aurora, OH). Perifosine
(PER) was obtained from Cayman Chemical (Ann Arbor,
MI). All drugs were used without further puriﬁcation. Drugs
were added to cells at ﬁnal concentrations of 1–10μMP E R ,
0.5μMA U R ,2 0m MN A C ,a n d1 . 0m MB S O .P E Ra n dA U R
were dissolved in ethanol and dimethyl sulfoxide (DMSO),
respectively, and then diluted with 0.9% sodium chloride
(Hospira,LakeForest,IL),NACwasdissolvedin1Msodium
bicarbonate (pH 7.0) and BSO was dissolved in PBS. The
required volume of each drug was added directly to complete
cell culture media on cells to achieve the desired ﬁnal
concentrations. All cells were placed in a 37
◦C incubator and
harvested at the time points indicated.
2.3. Detection of Activated Akt and Total Akt Levels. Cells
were harvested after 24 hours drug exposure, washed with
PBS, and then lysed with cell lysis buﬀer. Cell lysates were
standardized for protein content and resolved by SDS-
PAGE. Nitrocellulose blots were probed with rabbit antiAkt,
antiphospho-Akt Ser473 (Cell Signaling Technologies, Bev-
erly, MA), or antiGAPDH (Cell Signaling) antibodies.
2.4. Glutathione Assay. Cell pellets were thawed and homog-
enized in 50mM PO4 buﬀer (pH 7.8) containing 1.34mM
diethylenetriaminepentaacetic acid (DETAPAC) buﬀer. Total
glutathione content was determined by the method of
Anderson [22]. Reduced glutathione (GSH) and glutathione
disulﬁde (GSSG) were distinguished by addition of 2μL
of a 1 : 1 mixture of 2-vinylpyridine and ethanol per
30μL of sample followed by incubation for 1 hour and
assayed as described previously [23]. All glutathione deter-
minations were normalized to the protein content of whole
homogenates using the method of Lowry et al. [24].
2.5. Clonogenic Cell Survival Experiments. C e l l sw e r et r e a t e d
with PER for 24 hours prior to each clonogenic survival
experiment. In the indicated experiments, cells were treated
with NAC, BSO, or AUR for 1 hour before and during
PER exposure. Attached cells from experimental dishes were
trypsinized with 1mL trypsin-EDTA (CellGro, Herndon,
VA) and inactivated with DMEM containing 10% fetal
bovine serum (Hyclone). The cells were diluted and counted
using a Coulter counter. Cells were plated at low density
(150–1000 per plate), and clones were allowed to grow in
a humidiﬁed 5% CO2,3 7
◦C environment for 14 days in
complete medium, in the presence of 0.1% gentamicin. Cells
were ﬁxed with 70% ethanol and stained with Coomassie
blue for analysis of clonogenic cell survival as previously
described [25].
Individual assayswere performedwith multiple dilutions
with at least four cloning dishes per data point, repeated in
at least 3 separate experiments.
2.6. Thioredoxin Reductase Assay. Thioredoxin reductase
(TrxRed) activity was determined spectrophotometrically
using the method of Holmgren and Bjornstedt [26]. Enzy-
matic activity was determined by subtracting the time-
dependent increase in absorbance at 412nm in the pres-
ence of the TR activity inhibitor, aurothioglucose from
total activity. One unit of activity was deﬁned as 1μM
TNBformed/(min·mgprotein).Proteinconcentrationswere
determined by the Lowry assay [24].
2.7. Statistical Analysis. Statistical analysis was done using
GraphPad Prism version 4 for Windows (GraphPad Soft-
ware, San Diego, CA). To determine diﬀerences between 3
or more means, one-way ANOVA with Tukey posttests were
performed. Error bars represent the standard error of the
mean. All statistical analysis was performed at the P<. 05
level of signiﬁcance.
3. Results
3.1. Eﬀect of Perifosine on Akt Expression. To determine the
eﬀect of PER on Akt expression in HNSCC, FaDu, Cal-
27, and SCC-25 cells were treated with 5μMP E Rf o r2 4
hours then harvested for the detection of activated Akt
(pAkt) and total Akt. Activated Akt was detected in all 3
cell lines but varied in their expression levels (Figure 1). PER
completelyinhibitedtheexpressionofpAktinFaDuandCal-
27 cells and partially inhibited pAkt expression in SCC-25
cells (Figure 1). Total Akt was also inhibited by PER in Cal-
27 cells (Figure 1). These results conﬁrm that PER inhibited
pAkt activity in HNSCCs.
3.2. Eﬀect of Perifosine on Cells Growth and Survival. To
investigate the eﬀect of PER on human head and neck
squamous carcinoma cell growth, FaDu, Cal-27, and SCC-
25 cells were treated with increasing doses of PER (1–10μM)
and then counted at 0, 24, 48, and 72 hours after treatment.
P E Ra t1 ,5 ,a n d1 0μM inhibited FaDu cell growth after 72
hours (Figure 2(a)) while only 5 and 10μM PER inhibitedJournal of Oncology 3
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Figure 1: Eﬀect of perifosine (PER) on Akt expression. Akt
phosphorylation in FaDu, Cal-27, and SCC-25 cells was assayed
by Western blots (50μg protein loaded in each well) for Akt and
phosphor-Akt Ser473 in the presence or absence of 5μMP E Rf o r
24 hours. GAPDH was used as a loading control.
Cal-27 growth after 72 hours (Figure 2(b)). SCC-25 cells did
not respond to any of the PER doses over a 72-hour period
(Figure 2(c)). When we analyzed clonogenic survival after 24
hours of treatment with PER, we observed that 1μMP E R
did not aﬀect survival in any of the cells lines but 5 and
10μM PER signiﬁcantly decreased survival in FaDu and Cal-
27 cells compared to control (P<. 01, Figure 2(d)). SCC-25
cells were again resistant to PER treatment with 10μMP E R
causing a slight but nonsigniﬁcant decrease in SCC-25 cells
compared to control (Figure 2(d)). These results show that
PER causes growth arrest and cytotoxicity in HNSCC cells
but these aﬀects are dose dependent and vary by cell type.
3.3. Perifosine Induced Disruptions in Glutathione Metabolism
Consistent with Oxidative Stress. We examined if oxida-
tive stress could be contributing to the growth inhibitory
and cytotoxic eﬀects of PER by measuring glutathione
(GSH/GSSG)levelsinthecells.TheGSH/GSSGredoxcouple
represents a major small molecular weight thiol-disulﬁde
redox buﬀer in cells [27]. The amount of total GSH that
was oxidized (GSSG) was used to calculate percentage GSSG
(%GSSG). Consequently, an increase in %GSSG is believed
tosignifyashifttowardsamorehighlyoxidizingintracellular
environment indicative of oxidative stress [27]. We analyzed
GSH/GSSG levels in FaDu, Cal-27, and SCC-25 cells after
treatment with 5μM PER for 24 hours. We chose to further
analyze the eﬀects of 5μM PER in FaDu and Cal-27 cells
because it was a clinically achievable dose and well under
mean steady state plasma concentrations (16.2μM) achieved
in patients with solid tumors after a maximum tolerated
dose of 200mg PER per day [12]. We analyzed the eﬀects
of 10μM PER in SCC-25 cells because this was the only
dose that showed slight cytotoxicity in the clonogenic cell
survival assay (Figure 2(d)). PER caused an increase in
total GSH levels in Cal-27 and SCC-25 cells compared
to control which suggests that PER induced the synthesis
and accumulation of total GSH in an attempt to maintain
the redox buﬀering capacity of the intracellular reducing
environment (Figure 3(a)). PER did not signiﬁcantly change
total GSH levels in FaDu cells (Figure 3(a)). Increases in
GSSG were observed when all cell lines were treated with
PER although this eﬀect was only signiﬁcant in FaDu cells
(Figure 3(b)). When we calculated the eﬀect of PER on
%GSSG, all 3 cell lines demonstrated signiﬁcant increases
in %GSSG compared to control cells with FaDu showing
the greatest increase in %GSSG and SCC-25 showing the
least (Figure 3(c)). These results support the hypothesis that
the toxicity of PER may be in part mediated by disruptions
in GSH and/or thiol metabolism consistent with causing
oxidative stress.
3.4. PER-Induced Disruptions in Glutathione Metabolism and
Cytotoxicity Are Inhibited by NAC. To further analyze the
involvement of oxidative stress in PER-induced cytotoxicity,
FaDu, Cal-27, and SCC-25 cells were treated with 20mM
of the thiol antioxidant N-acetyl cysteine (NAC) for 1 hour
before and during exposure to PER, then analyzed for
GSH/GSSG levels and clonogenic survival. Treatment with
NAC alone signiﬁcantly increased GSH levels in SCC-25 cells
and also increased GSH in the presence of PER in SCC-25
cells (Figure 3(a)). Additionally, NAC suppressed the PER-
induced increase in GSSG in all 3 cell lines with FaDu and
Cal-27 reaching signiﬁcance (Figure 3(b)). However, PER-
induced increases in %GSSG were signiﬁcantly suppressed
by NAC in all 3 cell lines which were comparable to NAC
alone (Figure 3(c)). When we analyzed the eﬀect of NAC
on PER-induced cytotoxicity, NAC partially but signiﬁcantly
rescued the cytotoxicity induced by the combination of PER
(36%: NAC + PER versus 83%: PER, P<. 05) in FaDu cells
(Figure 3(d)). NAC did not signiﬁcantly rescue Cal-27 and
SCC-25 cells from PER-induced cytotoxicity (Figure 3(d)).
Taken together, Figure 3 supports the hypothesis that PER
induces disruptions in thiol metabolism consistent with
oxidative stress, which was reversed by NAC, and PER-
induced cytotoxicity in FaDu cells may be due in part to
increases in oxidative stress.
3 . 5 .P E R - I n d u c e dC y t o t o x i c i t yI sE n h a n c e db yB u t h i o n i n e
Sulfoximine. To determine if GSH depletion would further
enhance the cytotoxicity induced by PER, Cal-27, and SCC-
25 cells were treated with 1mM BSO, which is an inhibitor
of GSH synthesis, for 1 hour before and during treatment
with PER for 24 hours then analyzed for clonogenic survival
and GSH/GSSG. We did not study the eﬀect of BSO on
PER-induced cytotoxicity in FaDu cells since PER caused
such extensive cell killing as a single agent in this cell line.
The results indicate that the cell killing observed with PER
in Cal-27 was signiﬁcantly enhanced by BSO (77%: BSO +
PER versus 56%: PER, P<. 05, Figure 4(a)). Additionally,
SCC-25 cells which were initially resistant to PER treatment
(Figure 2(d)) became sensitized to PER in the presence
of BSO (44%: BSO + PER versus 11%: PER, P<. 05,
Figure 4(a)), but this sensitization was not comparable to
the cytotoxicity induced by PER in FaDu (83%) and Cal-
27 cells (56%, Figure 2(d)). BSO alone and in the presence
of PER signiﬁcantly depleted total GSH to less than 10%
of control cells in Cal-27 but only depleted 35% of total
GSH in SCC-25 cells (Figure 4(b)). Furthermore, BSO alone
andincombinationwithPERsigniﬁcantlyincreased%GSSG
in Cal-27 cells compared to control cells which was not4 Journal of Oncology
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Figure 2:Eﬀectofperifosine(PER)inheadandneckcancercellgrowthandsurvival.FaDu(a),Cal-27(b),andSCC-25(c)cellsweretreated
with 1, 5, and 10μmol/L PER and grown for 72 hours. (d) Cells were treated with 1–10μM PER for 24 hours then plated for clonogenic
survival. Clonogenic cell survival data were normalized to control (CON). Error bars represent ± 1SD of N = 4–6 experiments performed
on diﬀerent days with at least 2 cloning dishes taken from 1 treatment dish. ∗, P<. 05 versus control.
observed in SCC-25 cells (Figure 4(c)). These data show
that signiﬁcant depletion of glutathione (GSH) with BSO
enhances the cytotoxicity observed with PER and the extent
of sensitization may be due to the degree of GSH depletion
and induction of GSSG.
3 . 6 .P E R - I n d u c e dC y t o t o x i c i t yI sE n h a n c e db yA u r a n o ﬁ n .
Since BSO did not signiﬁcantly enhance PER-induced cell
killing in SCC-25 cells to that of PER-induced cell killing
observed in FaDu and Cal-27 (Figure 2(d)), we determined
ifinhibitionofthioredoxin(Trx)metabolismwouldenhance
PER-induced cell killing in SCC-25 cells and compared
the results to those of Cal-27. We pretreated cells with
0.5μM AUR for 1 hour before and during exposure to PER
(Figure 4). We chose this dose of 0.5μMA U Rb e c a u s ei tw a s
shown to inhibit thioredoxin reductase (TrxRed) activity by
approximately 50% in Cal-27 and SCC-25 cells compared to
control cells (Table 1). AUR caused about 30% cell killing in
both cell lines compared to control (Figure 4). Interestingly,
AUR did not further enhance PER-induced cell killing in
Cal-27 cells but AUR did sensitize SCC-25 cells to PER-
induced cell killing which was now comparable to PER-
induced cell killing in Cal-27 cells (56%: AUR + PER [SCC-
25] versus 56%: PER [Cal-27], Figure 4). Table 1 shows that
AUR alone and in combination with PER did in fact inhibit
TrxRed activity in Cal-27 and SCC-25 cells. PER alone did
not aﬀect TrxRed activity in any of the cell lines (Table 1).
The data in Figure 4 and Table 1 suggest that inhibition
of GSH and Trx metabolism pathways enhance sensitivity
to PER.Journal of Oncology 5
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Figure 3: Eﬀect of perifosine (PER) and N-acetyl-cysteine (NAC) on total glutathione (GSH) levels (a), glutathione disulﬁde (GSSG) levels
(b), percentage glutathione disulﬁde (%GSSG) levels (c), and cytotoxicity (d) in head and neck cancer cells. Cells were treated with 5μM
PER (FaDu and Cal-27) or 10μM PER (SCC-25) for 24 hours with or without treatment with 20mM NAC for 1 hour before and during
PER exposure. (a)–(c) Cells were harvested for glutathione analysis using the spectrophotometric recycling assay. Error bars represent ± 1SD
of N = 4 experiments. (d) Cells were analyzed for clonogenic survival and the data were normalized to control (CON). Error bars represent
± 1SD of N = 3 experiments performed on diﬀerent days with at least 2 cloning dishes taken from 1 treatment dish. ∗, P<. 001 versus
control; , P<. 001 versus respective treatment without NAC.
Table 1
Thioredoxin reductase activity (U/mg protein)
Cell line CON AUR PER AUR/PER
Cal-27 0.05 ±0.02 0.03 ±0.01 0.07 ±0.01 0.01 ±0.001
SCC-25 0.10 ±0.003 0.05 ±0.04 0.09 ±0.02 0.04 ±0.04
3.7. Thiol Antioxidant Status Predicts Response to Perifosine.
Since each head and neck cell line evaluated in these studies
varied in their response to PER (Figures 1 and 2), and
we demonstrated that disrupting GSH or Trx antioxidant
pathways sensitized certain cell lines to PER (Figure 4), we
determined if GSH or TrxRed activity predicted response
to PER. We plotted the surviving fraction of each cell line
in response to PER as a function of TrxRed activity at
control levels (Figure 5(a))a n dt o t a lG S Hc o n t e n ta tc o n t r o l
levels (Figure 5(b)). The results showed that TrxRed activ-
ity signiﬁcantly correlated with PER-induced cytotoxicity,
with FaDu, which demonstrated the greatest cell killing
in response to PER (Figure 2(d)), having the least TrxRed
activity (Figure 5(a)), and SCC-25 cells which were resistant
to PER (Figure 2(d)), having the highest level of TrxRed
activity (r2 = 0.8995, Figure 5(a)). Additionally, total GSH
levels also correlated with PER-induced cytotoxicity, with
FaDu cells having high GSH levels compared to the other cell
lines and SCC-25 cells having low GSH levels (r2 = 0.7286,
Figure 5(b)). These data suggest that cells with high TrxRed
activity and low total GSH levels may be resistant to PER and
cells with low TrxRed activity and high GSH content may be
sensitive to PER.6 Journal of Oncology
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Figure 4: Eﬀect of inhibitors of glutathione and thioredoxin metabolism on perifosine (PER) toxicity in head and neck cancer cells. (a)
Cal-27 and SCC-25 cells were treated with 5μM PER (Cal-27) or 10μM PER (SCC-25) for 24 hours with or without treatment with 1mM
buthionine sulfoximine (BSO) for 1 hour before and during PER exposure. (b)-(c) Cells were treated as stated above and harvested for total
glutathione (GSH) levels (b), and percentage glutathione disulﬁde (%GSSG) levels (c) using the spectrophotometric recycling assay. Error
bars represent ± 1SD of N = 3 experiments. (d) Cal-27 and SCC-25 cells were treated with 5μM PER (Cal-27) or 10μM PER (SCC-25) for
24 hour with or without treatment with 0.5μM Auranoﬁn (AUR) for 1 hour before and during PER exposure. Clonogenic cell survival data
were normalized to control (CON). Error bars represent ± 1SD of N = 3 experiments performed on diﬀerent days with at least 4 cloning
dishes taken from 1 treatment dish. ∗, P<. 001 versus control; , P<. 05 versus respective treatment without BSO or AUR.
4. Discussion
PER as a single agent has shown favorable responses
in patients with advanced soft tissue sarcomas [14]a n d
Waldenstrom macroglobulinemia [28]. However, responses
to PER in patients with common solid tumors have been
disappointing and have not justiﬁed the further investigation
of PER as a single agent. In this study we investigate the role
oxidative stress plays in the mechanism of PER and show
that sensitivity to PER may be enhanced by disrupting thiol
antioxidant metabolism pathways and increasing oxidative
stress in head and neck cancer cells.
Akt expression and hyperactivation is a frequent event
in HNSCC and strongly correlates with disease progression
[8, 29]. The HNSCC cell lines used in this study, FaDu,
Cal-27, and SCC-25 all expressed the activated form of Akt
(pAkt, Figure 1), which was inhibited by 24 hours treatment
with 5μM PER. Although pAkt was inhibited in all cases,
sensitivity to PER varied among the cell lines with FaDu
exhibiting the greatest growth inhibition and cytotoxicity
and SCC-25 exhibiting no response (Figure 2(d)). Never-
theless, these data support ﬁndings by Kondapaka et al.
(2003), who showed that 5μM PER for 24 hours inhibited
pAktexpressionandgrowthinPC-3prostatecarcinomacells
[21] and Patel et al. who showed antiproliferative eﬀects
with 0.6–8.9μM PER in head and neck cancer cells [30].
AdditionallyweobservedthatpAktwasexpressedatdiﬀerent
levels in the 3 cell lines with FaDu showing the highest
expression and SCC-25 showing the least (Figure 1). Since
FaDu cells with the highest expression of pAkt were the mostJournal of Oncology 7
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Figure 5:Associationofperifosine-(PER-)inducedcytotoxicitywithglutathione(GSH)contentandthioredoxinreductaseactivity(TrxRed)
in head and neck cancer cells. FaDu, Cal-27, and SCC-25 cells were analyzed for mean baseline TrxRed activity (a) and mean total GSH
content (b) and compared to their respective mean surviving fraction in response to 5μM PER (FaDu and Cal-27) or 10μM PER (SCC-25).
sensitive to the Akt inhibitor PER and SCC-25 cells with
relatively low pAkt expression were resistant to PER, it is
possible that tumors with high pAkt expression are more
susceptible to Akt pathway inhibitors than tumors with low
pAkt expression.
Activation of the Akt pathway is crucial for cell survival
and cellular redox status is involved in the reversible activa-
tionandinactivationofthispathway[4,31,32].Forexample,
moderate levels of ROS activate Akt pathway signaling and
promote cell survival, but high or chronic oxidative stress
inhibits this pathway resulting in apoptosis [4, 31–34]. Since
cancer cells are under increased metabolic oxidative stress
compared to normal cells and the Akt pathway may be
activated for survival under these oxidizing conditions, we
proposed that inhibition of the Akt pathway with PER would
increase oxidative stress to such an extent that would render
cancer cells sensitive to further increases in oxidative stress.
We investigated the eﬀects of PER on oxidative stress by
analyzing glutathione (GSH/GSSG) levels. The glutathione
system is a major intracellular redox buﬀer in the cell
and is involved in the detoxiﬁcation of H2O2 and organic
hydroperoxides [27] and the ratio of GSH to GSSG can be
used as a reﬂection of intracellular redox status [27]. PER
induced signiﬁcant increases in %GSSG in all 3 cell lines
compared to control cells (Figure 3(c)) which indicated an
increase in oxidative stress and suggests that inhibition of
Akt may be involved in increasing oxidative stress. To further
support this idea, the thiol antioxidant NAC was able to
completely suppress the increase in %GSSG in all 3 cell lines
(Figure 3(c)). Additionally, NAC was able to partially but
signiﬁcantly reversethe cytotoxicity induced by PER in FaDu
cellssuggestingthatincreasedoxidativestresswasinvolvedin
PER-induced cytotoxicity in this cell line (Figure 3(d)).
To further probe the role of GSH in the eﬀects of PER, we
used BSO, an inhibitor of glutamate cysteine ligase, which is
believed to be the rate-limiting enzyme in the synthesis of
GSH [35, 36] in Cal-27 and SCC-25 cells. Previous studies in
our laboratory have shown that BSO signiﬁcantly depleted
GSH pools in breast and head and neck cancer cells while
sensitizing cancer cells to chemotherapy agents [37, 38]. BSO
has also been used in clinical trials for cancer therapy to
enhance the cytotoxicity of chemotherapeutic agents [39]. In
the present studies, BSO was found to signiﬁcantly increase
the cytotoxicity induced by PER in Cal-27 cells (Figure 4(a)).
As expected, BSO signiﬁcantly decreased total GSH levels
and increased %GSSG in Cal-27 cells as a single agent and
in combination with PER (Figure 4(b)), which suggests that
inhibition of GSH synthesis further enhanced the oxidative
stress induced by PER and further sensitized these cells to
the toxicity of PER in Cal-27 cells.
Overall SCC-25 cells were more resistant to PER treat-
ment than FaDu and Cal-27 cells (Figures 1 and 2). We
also observed that BSO was not as eﬀective in SCC-25
cells as in Cal-27 cells at sensitization to PER (Figure 4(a)),
which was evident in the lack of signiﬁcant GSH depletion
in this cell line (Figure 4(b)). Although there was a trend
toward an increase in %GSSG in BSO + PER compared
to PER alone in SCC-25 cells (Figure 4(c)), this increase
was not signiﬁcant and was not nearly as great as the
BSO + PER-induced increase in %GSSG observed in Cal-
27 cells (Figure 4(c)). These observations suggest that PER-
induced cytotoxicity in SCC-25 cells is less dependent on
the glutathione/glutathione peroxidase system than in Cal-
27 cells. Preliminary experiments in our laboratory support
these observations and show that PER induced an increase
in GPx activity in Cal-27 cells but not SCC-25 cells (data
not shown). Therefore, we propose that other antioxidant
systems, such as the thioredoxin (Trx) system may be
involved in PER-induced cytotoxicity in SCC-25 cells.
The Trx system is a highly conserved ubiquitous system
comprised of thioredoxin reductase (TrxRed), thioredoxin
(Trx), thioredoxin peroxidases (a.k.a., peroxiredoxins), and
NADPH [40]. The Trx system plays an important role in
the redox regulation of multiple intracellular processes and8 Journal of Oncology
resistance to cytotoxic agents that induce oxidative stress
[41, 42]. TrxRed is a selenocysteine-containing protein that
catalyzes the reduction of Trx using NADPH as a reducing
agent [40]. TrxRed has been shown to initiate signaling
pathways in response to oxidative stress that play a role
in protecting the cell from oxidative stress and is therefore
believed to be a potential target for cytotoxic agents that
induce oxidative stress [40, 43, 44].
To investigate the role of Trx metabolism in SCC-25
cells we used Auranoﬁn (S-triethylphosphinegold(I)-2,3,4,6-
tetra-O-acetyl-1-thio-b-Dglucopyranoside (AUR)), which is
a relatively speciﬁc inhibitor of TrxRed (Table 1). AUR
belongs to the gold(I)-based drug class utilized in the
treatment of rheumatoid arthritis [45] and has been shown
to stimulate the mitochondrial production of hydrogen per-
oxide [46, 47]. AUR signiﬁcantly sensitized SCC-25 cells to
PER (Figure 4(d)) toagreaterextentthanBSO(Figure 4(a)),
which was comparable to the PER-induced cytotoxicity
seen in Cal-27 (Figure 2(d)). Interestingly, AUR did not
signiﬁcantly sensitize Cal-27 cells to PER (Figure 4(d)). This
further supports the idea that the Trx pathway was more
involved in PER-induced cytotxicity in SCC-25 cells than
Cal-27 cells, in which the GSH pathway appeared to be more
important.
We expected that BSO or AUR would sensitize Cal-27
and SCC-25 cells to PER to a greater extent than what we
observed in Figures 4(a) and 4(d) based on the fact that
both BSO, AUR and PER all induce oxidative stress as single
agents and should be mechanistically linked. However, we do
acknowledge that more extensive analysis of dose responses
for BSO + PER and AUR + PER is needed (i.e., isobologram
analysis) and our data shown in Figure 4 does not address
this issue of mechanistic linkage. On the other hand, our
data strongly suggests the opposite, in that BSO or AUR
in combination with PER may be mechanistically unlinked
since BSO + PER (in Cal-27 and SCC-25) and AUR + PER
(in SCC-25) appear to be additive (Figures 4(a) and 4(d)).
BSO inhibits the synthesis of GSH, AUR inhibits TrxRed
activity and PER inhibits Akt pathway signaling, therefore,
the mechanism of action of these agents is not linked.
However, BSO, AUR and PER all have signiﬁcant eﬀects on
oxidative stress which further justiﬁes the need for more
extensive dose response analysis of these drugs to determine
additivity or synergy.
It is important to note that SCC-25 cells possess twice
as much TrxRed activity as Cal-27 cells and that Cal-
27 cells possess about twice the amount of total GSH
compared to SCC-25 cells (Table 1, Figure 4). This led us
to propose that total GSH and TrxRed activity may predict
response to PER in head and neck cancer cells. To gain
some insight into this relationship we plotted TR activity
and total GSH of each cell line at control levels against
the surviving fraction in response to PER (Figure 5). The
results suggested that high TrxRed activity and low total
GSH (as in SCC-25 cells) rendered the cells resistant to PER
treatment, while low TrxRed activity and high total GSH
(as in FaDu cells) rendered cells sensitive to PER (Figure 5).
These results support data by Ceccarelli et al. [48], who
showed that lung cancer cells with high Trx expression levels
had a more aggressive phenotype, but were more sensitive to
TrxinhibitionthancellswithlowTrxexpressionlevels.These
results also may account for why TrxRed is upregulated in
many tumor cells and supports the speculation that drug-
resistant cells may be more susceptible to the inhibition
of TrxRed to promote cytotoxicity and susceptibility to
otherchemotherapeuticdrugs.Additionally,ourpreliminary
experiments have shown higher GPx activity in FaDu cells
compared to Cal-27 and SCC-25, and GPx activity appeared
to correlate with sensitivity to PER similar to that shown
in Figure 5(b) (data not shown). We are currently repeating
these experiments, but these encouraging results further
suggest that there may be a higher level of GSH metabolism
in FaDu cells compared to SCC-25 cells.
Overall, the data provided here support the conclusion
that PER induces oxidative stress in HNSCC cells and
disrupting thiol antioxidant metabolic pathways enhances
susceptibility to PER via oxidative stress. These data also
support the speculation that TrxRed activity and total GSH
levels may help to predict response to PER. Finally, these
data provide a biochemical rationale for the use of inhibitors
of GSH and Trx metabolism in combination with PER to
enhance susceptibility of HNSCC cells to clonogenic cell
killing by PER in combined modality cancer therapies.
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